aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report) saw strong trading volume on Wednesday . 4,792,835 shares traded hands during trading, an increase of 145% from the previous session's volume of 1,959,777 shares.The stock last traded at $6.12 and had previously closed at $5.24.
Analyst Upgrades and Downgrades
ATYR has been the topic of a number of research reports. Wells Fargo & Company boosted their price objective on aTyr Pharma from $17.00 to $25.00 and gave the company an "overweight" rating in a research note on Friday, June 20th. HC Wainwright reissued a "buy" rating and issued a $35.00 price target on shares of aTyr Pharma in a research report on Wednesday, June 4th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $20.20.
Check Out Our Latest Report on aTyr Pharma
aTyr Pharma Trading Up 3.0%
The firm has a 50-day moving average of $5.03 and a 200-day moving average of $3.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.79 and a current ratio of 7.79. The firm has a market capitalization of $509.53 million, a P/E ratio of -7.07 and a beta of 0.89.
aTyr Pharma (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.02. On average, equities research analysts anticipate that aTyr Pharma, Inc. will post -0.91 EPS for the current fiscal year.
Institutional Investors Weigh In On aTyr Pharma
Several large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its position in aTyr Pharma by 467.8% during the fourth quarter. JPMorgan Chase & Co. now owns 178,532 shares of the company's stock valued at $646,000 after acquiring an additional 147,092 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in aTyr Pharma during the fourth quarter valued at $881,000. Charles Schwab Investment Management Inc. purchased a new stake in aTyr Pharma during the fourth quarter valued at $144,000. Bank of America Corp DE purchased a new stake in aTyr Pharma during the fourth quarter valued at $330,000. Finally, Jane Street Group LLC purchased a new stake in aTyr Pharma during the fourth quarter valued at $720,000. 61.72% of the stock is currently owned by institutional investors.
About aTyr Pharma
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
See Also
Before you consider aTyr Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and aTyr Pharma wasn't on the list.
While aTyr Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
